%0 Journal Article
%A Sannemann, Lena
%A Bartels, Claudia
%A Brosseron, Frederic
%A Buerger, Katharina
%A Fliessbach, Klaus
%A Freiesleben, Silka Dawn
%A Frommann, Ingo
%A Glanz, Wenzel
%A Heneka, Michael
%A Janowitz, Daniel
%A Kilimann, Ingo
%A Kleineidam, Luca
%A Lammerding, Dominik
%A Laske, Christoph
%A Munk, Matthias H J
%A Perneczky, Robert
%A Peters, Oliver
%A Priller, Josef
%A Rauchmann, Boris Stephan
%A Rostamzadeh, Ayda
%A Roy-Kluth, Nina
%A Schild, Ann-Katrin
%A Schneider, Anja
%A Schneider, Luisa-Sophie
%A Spottke, Annika
%A Spruth, Eike Jakob
%A Teipel, Stefan
%A Wagner, Michael
%A Wiltfang, Jens
%A Wolfsgruber, Steffen
%A Duezel, Emrah
%A Jessen, Frank
%T Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.
%J Journal of Alzheimer's disease
%V 100
%N 1
%@ 1387-2877
%C Amsterdam
%I IOS Press
%M DZNE-2024-00846
%P 193 - 205
%D 2024
%X The NIA-AA Research Framework on Alzheimer's disease (AD) proposes a transitional stage (stage 2) characterized by subtle cognitive decline, subjective cognitive decline (SCD) and mild neurobehavioral symptoms (NPS).To identify participant clusters based on stage 2 features and assess their association with amyloid positivity in cognitively unimpaired individuals.We included baseline data of N = 338 cognitively unimpaired participants from the DELCODE cohort with data on cerebrospinal fluid biomarkers for AD. Classification into the AD continuum (i.e., amyloid positivity, A+) was based on Aβ42/40 status. Neuropsychological test data were used to assess subtle objective cognitive dysfunction (OBJ), the subjective cognitive decline interview (SCD-I) was used to detect SCD, and the Neuropsychiatric Inventory Questionnaire (NPI-Q) was used to assess NPS. A two-step cluster analysis was carried out and differences in AD biomarkers between clusters were analyzed.We identified three distinct participant clusters based on presented symptoms. The highest rate of A+ participants (47.6
%K Humans
%K Male
%K Female
%K Amyloid beta-Peptides: cerebrospinal fluid
%K Amyloid beta-Peptides: metabolism
%K Aged
%K Cognitive Dysfunction: cerebrospinal fluid
%K Cognitive Dysfunction: psychology
%K Cognitive Dysfunction: diagnosis
%K Biomarkers: cerebrospinal fluid
%K Peptide Fragments: cerebrospinal fluid
%K Neuropsychological Tests
%K Alzheimer Disease: cerebrospinal fluid
%K Alzheimer Disease: psychology
%K Alzheimer Disease: diagnosis
%K Middle Aged
%K Cohort Studies
%K Aged, 80 and over
%K Cluster Analysis
%K Alzheimer’s disease (Other)
%K Alzheimer’s disease (Other)
%K Alzheimer’s disease continuum (Other)
%K NIA-AA stage 2 (Other)
%K amyloid (Other)
%K cerebrospinal fluid biomarkers (Other)
%K neuropsychiatric symptoms (Other)
%K preclinical Alzheimer’s disease (Other)
%K subjective cognitive decline (Other)
%K Amyloid beta-Peptides (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%K Peptide Fragments (NLM Chemicals)
%K amyloid beta-protein (1-42) (NLM Chemicals)
%K Alzheimer’s disease continuum (Other)
%K preclinical Alzheimer’s disease (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38848176
%R 10.3233/JAD-231335
%U https://pub.dzne.de/record/270674